Inhibition of poly(ADP-ribose) pollyrnerase in cancer

被引：87

作者：

Plummer, Elizabeth Ruth ^{[1
]}

机构：

[1] Univ Newcastle, No Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England

来源：

CURRENT OPINION IN PHARMACOLOGY | 2006年 / 6卷 / 04期

关键词：

D O I：

10.1016/j.coph.2006.02.004

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase-1 (PARP-1) has been extensively investigated in the pre-clinical setting as a strategy for chemo- or radio-potentiation. Recent evidence has suggested that PARP inhibitors might be active as single agents in certain rare inherited cancers that carry DNA repair defects. As a result, potent PARP-1 inhibitors have in the past three years entered early clinical trials in cancer patients, and the final results of these trials are eagerly awaited.

引用

页码：364 / 368

页数：5

共 43 条

[41] Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds [J].

Tentori, L ;

Turriziani, M ;

Franco, D ;

Serafino, A ;

Levati, L ;

Roy, R ;

Bonmassar, E ;

Graziani, G .

LEUKEMIA, 1999, 13 (06) :901-909

[42]

Veuger SJ, 2003, CANCER RES, V63, P6008

[43] Cancer genes and the pathways they control [J].

Vogelstein, B ;

Kinzler, KW .

NATURE MEDICINE, 2004, 10 (08) :789-799

← 1 2 3 4 5 →